Faricimab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Faricimab |
| DrugBank ID | DB15303 |
| Brand Names (EU) | Vabysmo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.88% |
Approved Indication (EMA)
Vabysmo is indicated for the treatment of adult patients with: neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 98.88% | DL |
| 2 | pseudo-von Willebrand disease | 98.74% | DL |
| 3 | Glanzmann thrombasthenia | 98.39% | DL |
| 4 | drug-induced osteoporosis | 97.79% | DL |
| 5 | esotropia | 97.74% | DL |
| 6 | severe nonproliferative diabetic retinopathy | 97.25% | DL |
| 7 | HER2 positive breast carcinoma | 96.90% | DL |
| 8 | diabetic retinopathy | 96.75% | DL |
| 9 | respiratory syncytial virus infectious disease | 96.38% | DL |
| 10 | fetal and neonatal alloimmune thrombocytopenia | 96.08% | DL |
| 11 | breast tumor luminal A or B | 95.73% | DL |
| 12 | progesterone-receptor positive breast cancer | 95.72% | DL |
| 13 | normal breast-like subtype of breast carcinoma | 95.72% | DL |
| 14 | progesterone-receptor negative breast cancer | 95.64% | DL |
| 15 | progressive multiple sclerosis | 95.47% | DL |
| 16 | diabetic cataract | 95.05% | DL |
| 17 | non-syndromic esophageal malformation | 94.56% | DL |
| 18 | senile cataract | 93.88% | DL |
| 19 | nuclear senile cataract | 93.82% | DL |
| 20 | cortical cataract | 93.82% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.